CAR-T is an exciting new treatment which uses modified T-cells, a type of immune system white blood cell, to treat cancer. In the study of CAR-T with lymphoma, researchers are discovering that PET scans with FDG (a modified sugar molecule) predict long term response to CAR-T therapy. For patients who are not responding, this gives doctors time to switch to other treatment regimens without having to wait.
